Navigation Links
AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
Date:11/22/2011

IRVINE, Calif., Nov. 22, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced the recent presentation by Diana Shih, Ph.D., Associate Professor of Medicine, Division of Cardiology at the David Geffen School of Medicine at UCLA, at the 2011 American Heart Association (AHA) Scientific Sessions in Orlando, Florida.  Dr. Shih's presentation included information on research sponsored by the Company which demonstrated that dietary supplementation of AHRO-001 resulted in a 95% reduction in arterial plaque formation at the innominate artery when compared to the control group.

The study results also revealed significant reduction in plasma cholesterol and dietary cholesterol absorption in the test subjects that received HDCA. HDCA supplementation also improved HDL function as measured by cholesterol efflux assay. These factors indicate multiple methods of action for an anti-atherogenic effect, suggesting a clear potential for new anti-atherosclerotic therapy.

"We are extremely pleased with the results of the UCLA study and want to thank Dr. Shih for all of her efforts on this presentation," said Thomas W. Gardner, CEO of AtheroNova. "The data from this study confirms and enhances our initial research and understanding of the compounds. As a result, we are moving forward with the preparation of an Investigative New Drug (IND) application with the Food and Drug Administration (FDA) for our atherosclerotic plaque regression compounds, in addition to, preparations for entry into Phase I human trials during 2012."

"Presenting such positive data to an audience of industry peers at AHA validates the potential of AtheroNova's compounds," Gardner concluded. 

Dr. Shih's presentation can be viewed on the American Heart Association's website at www.scientificsessions.org'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
4. SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts
5. Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference
6. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
7. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
8. Micell Technologies Reports Preclinical Data for MiStentâ„¢ Drug-Eluting Coronary Stent to be Presented at EuroPCR
9. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
10. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
11. QPS Expands Into Toxicology Services With Acquisition of the Preclinical Unit of DCB Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... BioLife Solutions, Inc.,(OTC Bulletin Board: BLFS), ... hypothermic storage and cryopreservation media products for ... of its new quarterly,newsletter BioPreservation Today, a ... and processes, to maximize the yield and,function ...
... Md., Jan. 26 MaxCyte, Inc., the pioneer ... the presentation of the MaxCyte(R) STX(TM) Scalable Transfection ... Session, a joint program of the Association for ... Group (LRIG). The Rapid Fire Innovation Session showcases ...
... as subcontractor to Battelle for submission of proposals ... 26 Corgenix Medical Corporation (OTC Bulletin Board: ... test kits, has announced a collaboration with Battelle, ... whose business focus includes national security. Under the ...
Cached Biology Technology:BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 3The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009 2Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... is available in German . , Four ... year,s Heinz Maier-Leibnitz Prize, Germany,s top research award for young ... the prize, which has been awarded annually by the Deutsche ... of Education and Research since 1977, that the majority of ...
... is available in German . The gene ... by cell division. It causes the production of a protein ... to 15 % of all human genes. When this gene ... is inhibited. Thereby the gene plays a decisive role in ...
... is a familiar phenomenon, even if the phrase is not: ... it around the block. After jogging regularly for a few ... three. With regular exercise, the body adapts, becoming fitter and ... oxygen to the muscles. The muscles get stronger, and so ...
Cached Biology News:Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 2Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 3Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 4Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 5Symposium to look at genetic basis of exercise 2Symposium to look at genetic basis of exercise 3
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: